Nolazco A, Caldas M, Featherston M, Hernández A, Ares J, Rozanec J, Vallone C

Language: Spanish
References: 9
Page: 360-363
PDF size: 835.82 Kb.

ABSTRACT

Introduction: The use of lasers has been incorporated into medical practice since 1970. Presently the 980-nm laser diode is a valid treatment alternative for benign prostatic hyperplasia. It is a safe method providing the patient with a high rate of tissue vaporization that requires hospital stay of less than 24 hours. Recovery is rapid and patients present with very few irritative symptoms.
Objective: To evaluate results of laser diode use in benign prostatic hyperplasia.
Methods: The 980-nm laser diode was introduced in Argentina in November of 2007. Of the two hundred and forty-three patients operated on up to June of 2010, one hundred twenty-eight patients with eighteen-month follow-up were analyzed. Preoperative and postoperative Maximum Flow and International Prostate Symptom Score were evaluated and total joules of energy utilized, number of fibers utilized, and prostate volume were described.
Results: A statistically significant increase in Maximum Flow was observed as well as a statistically significant decrease in International Prostate Symptom Score after carrying out vaporization in prostates with mean volume of 71.36 (20- 159 mL range).
Conclusions: Prostatic vaporization with 980-nm laser diode has been a safe and effective technique in treating benign prostatic hyperplasia patients at the authors’ medical center. There is a minimum of bleeding and postoperative bladder wash is not required. Reabsorption syndrome is avoided and both length of time with catheter and hospital stay are shorter.

REFERENCES

1. Chapple CR. Lower urinary tract symptoms suggestive of benign prostatic obstruction-triumph: design and implementation. Eur Urol 2001;39 (Suppl 3):31-6.

2. Barry MJ. Medical outcomes research and benign prostatic hyperplasia. Prostate Suppl 1990;3:61-74.

3. Wheelahan J, Scott NA, Cartmill R. Minimally invasive laser techniques for prostatectomy: a systematic review. The ASERNIP-S review group. Australian Safety and Efficacy Register of New Interventional Procedures-Surgical. BJU Int 2000;86:805-15.

4. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008;180:246-9.

5. Tooher R, Sutherland P, Costello A, et al. A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. J Urol 2004;171:1773-81.

6. Issa MM. The evolution of laser therapy in the treatment of benign prostatic hyperplasia. Rev Urol 2005;7(Suppl 9):S15-22.

7. Shan HN, Mahajan AP, Sodha HS, et al. Prospective evaluation of the learning curve for holmium laser enucleation of the prostate. J Urol 2007;177:1468-74.

8. Shan HN, Mahajan AP, Sodha HS, et al: Perioperative complications of holmium laser enucleation of the prostate: experience in the first 280 patients, and a review of literature. BJU Int 2007;100:94-101.

9. Wendt-Nordahl G, Huckele S, Honeck P, et al. 980-nm Diode laser: a novel laser technology for vaporization of the prostate. Eur Urol 2007;52:1723-8.